Quick Answer
Climb Bio, Inc. reported Cash and Equivalents of $35.69 million for fiscal year 2025.
Climb Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $35.69M | -59.1% |
| 2024 | $87.23M | -6.3% |
| 2023 | $93.11M | +113.6% |
| 2022 | $43.59M | -7.1% |
| 2021 | $46.92M | +129.0% |
| 2020 | $20.49M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.80M | -82.3% | +13.8% |
| June 30, 2025 | $22.68M | -89.8% | -21.8% |
| March 31, 2025 | $29.02M | -72.4% | -66.7% |
| December 31, 2024 | $87.23M | -6.3% | -40.3% |
| September 30, 2024 | $146.18M | +154.9% | -34.5% |
| June 30, 2024 | $223.14M | +782.2% | +112.5% |
| March 31, 2024 | $105.03M | +205.0% | +12.8% |
| December 31, 2023 | $93.11M | +113.6% | +62.3% |
- Climb Bio, Inc. showed a decrease of -59.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Climb Bio, Inc.’s cash and equivalents has grown by 74.2% (from $20.49 million to $35.69 million).
- The most recent figure is from Climb Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: